News
XAIR
0.4950
+3.71%
0.0177
Beyond Air Unveils New Leadership and Growth Outlook
TipRanks · 5h ago
Midday Fly By: On Semi to acquire Synaptics, OpenAI leans toward 2027 IPO
TipRanks · 10h ago
Morning Movers: Shares of On Semi, Synaptics diverge after $7B transaction
TipRanks · 13h ago
Transcript: Beyond Air Q4 2026 Earnings Conference Call
Benzinga · 13h ago
Beyond Air Sees Calendar Year 2027 Sales $16.000M-$18.000M
Benzinga · 14h ago
Beyond Air narrows FY26 revenue view to $8M from $8M-$10M, consensus $8.08M
TipRanks · 14h ago
Beyond Air sees FY27 revenue $16M-$18M, consensus $12.7M
TipRanks · 14h ago
Beyond Air reports Q4 EPS (77c) vs. ($1.79) last year
TipRanks · 14h ago
Earnings Scheduled For June 26, 2026
Benzinga · 14h ago
Beyond Air Q4 EPS $(0.77) Misses $(0.57) Estimate, Sales $1.907M Miss $2.296M Estimate
Benzinga · 14h ago
Beyond Air fiscal FY revenue doubles on LungFit PH demand
Reuters · 14h ago
Beyond Air GAAP EPS of -$4.01 misses by $0.24, revenue of $7.7M misses by $0.38M
Seeking Alpha · 15h ago
*Beyond Air 4Q Rev $1.91M >XAIR
Dow Jones · 15h ago
*Beyond Air Sees 2026 Rev $8M >XAIR
Dow Jones · 15h ago
Beyond Air FY26 net loss narrows to $33.2 million; revenue more than doubles to $7.7 million
PUBT · 15h ago
BEYOND AIR OUTLOOK 2026 REVENUE $8 MILLION
Reuters · 15h ago
*Beyond Air 4Q Loss/Shr 77c >XAIR
Dow Jones · 15h ago
Press Release: Beyond Air(R) Reports Fourth -2-
Dow Jones · 15h ago
Press Release: Beyond Air(R) Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update
Dow Jones · 15h ago
Stock Market Today: Dow Jones Inches Up, S&P 500 And Nasdaq Futures Slip As Tech Selloff Gathers Pace— Apple, Beyond Air In Focus
Benzinga · 16h ago
More
Webull provides a variety of real-time XAIR stock news. You can receive the latest news about Beyond Air Inc through multiple platforms. This information may help you make smarter investment decisions.
About XAIR
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.